Clinical Trials Browser

OTHER_GOV × Lymphoma, Large B-Cell, Diffuse × Clear all

Cytokine Release Syndrome, Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04214626 2025-11-19

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Phase 2 Completed

60 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06793410 2025-06-05

Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation

Phase 2 Recruiting

100 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Papillomavirus Infections

NCT04668365 2025-04-25

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Phase 2 Suspended

59 enrolled

Lymphoid

Congenital Abnormalities, Lymphoma, Large B-Cell, Diffuse

NCT06822829 2025-02-12

REVERSE_2021

Recruiting

50 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03610061 2024-04-12

RaDD

Phase 1 Completed

34 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05715606 2023-07-05

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Phase EARLY_PHASE1 Unknown

18 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05164770 2021-12-21

Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Phase 3 Unknown

160 enrolled

Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05097443 2021-11-19

Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Phase 3 Unknown

130 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02733380 2020-04-01

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Phase 2 Unknown

20 enrolled

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02747732 2019-04-23

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Phase 2 Unknown

72 enrolled

Lymphoid

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Clinical Trials

NexCAR19

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

REVERSE_2021

RaDD

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL